The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Sanaz Memarzadeh receives $4.1M to develop immune therapies for ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Sanaz Memarzadeh of UCLA has received two grants totaling $4.1 million to develop advanced cell-based immune therapies for high-grade serous ovarian cancers that have become resistant to conventional treatments. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.
Cancer Policy

DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants.  The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

By Sara Willa Ernst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account